How PiVily intelligence is made

Evidence you can inspect.
Interpretation you can question.

PiVily is a founder-led education and intelligence platform. Dr. Osa Woghiren, PharmD is the accountable publisher. Founder expertise does not imply regulatory, employer, or institutional endorsement.

What we select

Developments are selected for relevance across safety science, reporting, evidence, technology, governance, communication, and professional practice. Selection considers the authority of the source, the clarity of its jurisdiction and status, and whether it offers a useful connection across disciplines or regions.

The Q4 2026 interim edition covers selected US, UK, EU/EEA, and Nigerian material. Nigeria’s July guidance is background context. This selection is not continuous worldwide regulatory surveillance.

What the labels mean

  • Source fact: the original publisher’s statement, linked directly.
  • PiVily commentary: an educational interpretation, not a new requirement.
  • Watchpoint: a pending question or future event, not an achieved outcome.
  • Link check: destination availability, not a judgment that guidance is current or applicable.

Dates and archived editions

Event/effective dates, official publication dates, PiVily source reviews, and publication updates are separate. Dates use America/New_York. Missing dates are identified rather than invented; month-only dates remain month-only.

Retrospective reports describe earlier periods and retain their review dates. The Q3 baseline covers material only through 11 August 2026. Material changes receive a dated correction or update note; cosmetic edits do not extend source coverage.

Responsibility and independence

Preparation and source checks may use software assistance. PiVily remains responsible for the published content. Direct official sources and their limitations remain available for readers to inspect.

Sponsorship and relevant interests must be disclosed. Sponsorship cannot purchase a predetermined conclusion. Read the editorial standards →

Corrections & updates

· Date-label correction

The Q4 interim edition and directory checks completed on 2 November in America/New_York were labelled 3 November using UTC. Their review dates and Q4 coverage end have been corrected to 2 November. This correction changes the chronology labels; it does not add a day of regulatory coverage or change the source conclusions.

Read the Q4 interim edition →

To request a correction, email info@pivilyglobal.com with the page, disputed statement, and supporting official source. Do not include confidential or patient-identifiable information.